Horizon Pharma Inc. (HZNP) Upgraded to Strong-Buy at Vetr Inc.
Vetr upgraded shares of Horizon Pharma Inc. (NASDAQ:HZNP) from a buy rating to a strong-buy rating in a research note published on Monday.
Other research analysts also recently issued reports about the company. Jefferies Group reiterated a buy rating and issued a $27.00 price target on shares of Horizon Pharma in a report on Thursday, August 4th. Goldman Sachs Group Inc. assumed coverage on Horizon Pharma in a report on Monday, June 6th. They issued a buy rating and a $24.00 price target on the stock. Brean Capital reiterated a buy rating on shares of Horizon Pharma in a report on Tuesday, August 2nd. Guggenheim reiterated a buy rating and issued a $30.00 price target on shares of Horizon Pharma in a report on Monday, August 1st. Finally, Stifel Nicolaus reiterated a buy rating and issued a $45.00 price target on shares of Horizon Pharma in a report on Wednesday, July 6th. One analyst has rated the stock with a sell rating, three have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of Buy and an average target price of $30.00.
Horizon Pharma (NASDAQ:HZNP) traded up 0.59% during mid-day trading on Monday, reaching $18.88. The company had a trading volume of 102,126 shares. Horizon Pharma has a 52 week low of $12.86 and a 52 week high of $23.70. The stock’s 50-day moving average price is $19.59 and its 200 day moving average price is $17.72. The firm’s market capitalization is $3.04 billion.
Horizon Pharma (NASDAQ:HZNP) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the consensus estimate of $0.50 by $0.12. The company had revenue of $257.40 million for the quarter, compared to the consensus estimate of $235.43 million. Horizon Pharma had a positive return on equity of 23.46% and a negative net margin of 0.34%. Horizon Pharma’s quarterly revenue was up 48.9% on a year-over-year basis. During the same period last year, the business posted $0.39 EPS. On average, equities research analysts predict that Horizon Pharma will post $2.15 EPS for the current year.
In other Horizon Pharma news, EVP Jeffrey W. Sherman sold 2,900 shares of Horizon Pharma stock in a transaction dated Tuesday, August 2nd. The stock was sold at an average price of $20.00, for a total transaction of $58,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 2.10% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the stock. Virginia Retirement System bought a new position in Horizon Pharma during the first quarter worth $282,000. Pacad Investment Ltd. raised its position in Horizon Pharma by 34.7% in the first quarter. Pacad Investment Ltd. now owns 67,867 shares of the biopharmaceutical company’s stock worth $1,125,000 after buying an additional 17,484 shares during the last quarter. Algert Global LLC raised its position in Horizon Pharma by 57.3% in the first quarter. Algert Global LLC now owns 20,872 shares of the biopharmaceutical company’s stock worth $346,000 after buying an additional 7,602 shares during the last quarter. Franklin Resources Inc. raised its position in Horizon Pharma by 5,195.9% in the first quarter. Franklin Resources Inc. now owns 1,276,730 shares of the biopharmaceutical company’s stock worth $21,155,000 after buying an additional 1,252,622 shares during the last quarter. Finally, BlackRock Group LTD raised its position in Horizon Pharma by 21.0% in the first quarter. BlackRock Group LTD now owns 100,919 shares of the biopharmaceutical company’s stock worth $1,672,000 after buying an additional 17,505 shares during the last quarter. Institutional investors and hedge funds own 85.25% of the company’s stock.
About Horizon Pharma
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.